
Lisa Salvatore
Council
About
About
Lisa Salvatore is a Medical Oncologist at the Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, and she is Professor at the School of Medicine and Surgery of the Università Cattolica del Sacro Cuore, Rome.
She graduated in Medicine in 2007 and specialized in Oncology in 2012 with honors at the University of Pisa. She obtained the second level Master’s degree in “Clinical Trials of Pharmaceuticals” at the Division of Pharmacology of the University of Pisa in 2012. In 2018 she obtained the title of PhD in “Clinical Physiopathology” with honors at the University of Pisa.
From May 2012 to August 2016 she worked as Medical Oncologist at the Medical Oncology Unit of Azienda Ospedaliero-Universitaria Pisana, Pisa.
From September 2016 to September 2018 she worked at the Medical Oncology Unit of the Azienda Universitaria Integrata di Verona and she was Professor at the School of Medicine and Surgery of the University of Verona.
Since 2012 she is involved in the writing and update of the Italian guidelines on colorectal cancer and since 2020 she is the Coordinator of National guidelines.
She is involved in the management of patients with gastrointestinal cancer, in particular colorectal, pancreatic and biliary tract cancer, and her main interest is the research, both clinical and translational, in the field of these diseases. She has conducted and she is conducting profit and no-profit clinical trials in colorectal, pancreatic and biliary tract cancer.
Publications
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Clin Colorectal Cancer. 2023 Jun 11
doi: 10.1016/j.clcc.2023.06.002 – PubMed ID: 37429749
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Clin Cancer Res. 2023 Jun 13
doi: 10.1158/1078-0432.CCR-22-3878 – PubMed ID: 37022350
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer. 2023 Apr
doi: 10.1136/jitc-2022-006633 – PubMed ID: 37085190